Nasulin intranasal insulin: Preliminary Phase IIa data

Preliminary data from a double-blind, U.S. Phase IIa trial in 94 patients showed that inhaled Nasulin in combination with basal insulin and oral diabetes agents missed the primary endpoint of significantly increasing the mean proportion of time spent in euglycemia from baseline as assessed by CGM vs. placebo (p=0.20). Nasulin also missed the secondary endpoints of a significant change from baseline in average glucose and serum fructosamine levels, respectively, vs. placebo. No critical safety signals were detected. Patients received Nasulin or placebo at the start of each meal for 6 weeks. Data will be presented at the American Association of Clinical Endocrinologists meeting in Boston in April. ...